In Brief: US_FDA approves a first-in-class live microbiota-based therapy to prevent recurrent Clostridium difficile infections
Ferring’s approval was based on the phase 3 PUNCH CD3 clinical trial, in which 177 adults received Rebyota and 85 placebo.
All participants had previously experienced a recurrent bout ofafter antibiotic treatment. During the trial, treatment success was defined as absence of recurrentinfection after 8 weeks. Of those treated with Rebyota, 78% met with success, versus 58% on placebo. Though the difference was modest, the
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Massively parallel knock-in engineering of human T cells - Nature BiotechnologyUnbiased selection of CAR-T cells is achieved by massively parallel knock-in engineering.
続きを読む »
In vivo development of immune tissue in human intestinal organoids transplanted into humanized mice - Nature BiotechnologyIn vivo development of immune tissue in human intestinal organoids transplanted into humanized mice
続きを読む »
A universal deep-learning model for zinc finger design enables transcription factor reprogramming - Nature BiotechnologyA universal deep-learning model for zinc finger design enables transcription factor reprogramming
続きを読む »
Spatial transcriptomics for profiling the tropism of viral vectors in tissues - Nature BiotechnologySpatial transcriptomics for profiling the tropism of viral vectors in tissues
続きを読む »
Large language models generate functional protein sequences across diverse families - Nature BiotechnologyA generative deep-learning model designs artificial proteins with desired enzymatic activities.
続きを読む »
Three-dimensional structured illumination microscopy with enhanced axial resolution - Nature BiotechnologyThree-dimensional structured illumination microscopy with enhanced axial resolution - NIBIBgov
続きを読む »